Product Information
DROXIDOPA 300 MG CAPSULE is a generic product labeled by Novadoz Pharmaceuticals LLC, priced at $1.8445 per EA under NDC 72205007490. Its NADAC has been published 172 times since Jun 21, 2023.
FDA first approved this application on Feb 18, 2021. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
300 mg/1
Manufacturer
Novadoz Pharmaceuticals LLCNDC
72205007490
Classification
Generic
Dosage Form
CAPSULE
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
DROXIDOPAApproval Type
Generic (ANDA)
FDA Application
ANDA211741FDA Approved
2/18/2021
TE Code
AB
On Market Since
2/19/2021
Pharmacological Classes
Price Statistics
The NADAC for DROXIDOPA 300 MG CAPSULE has been published 172 times since Jun 21, 2023, and over the history we have for it it has declined 27.8%. The table below summarizes its recorded NADAC range and movement.
| Current price | $1.8445 per EA |
|---|---|
| All-time high | $3.0478 (Nov 13, 2024) |
| All-time low | $1.8445 (Sep 23, 2026) |
| 52-week high | $2.8151 |
| 52-week low | $1.8445 |
| Median price | $2.5551 |
| Average price | $2.5599 |
| Largest weekly change | -14.0% (Sep 23, 2026) |
| Weeks tracked | 172 |
| Tracking since | Jun 21, 2023 |
Generic Alternatives
The matcher finds 6 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). None of the shown alternatives sit below the current price. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Novadoz Pharmaceuticals LLC manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Droxidopa market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of DROXIDOPA 300 MG CAPSULE?
The current National Average Drug Acquisition Cost (NADAC) for DROXIDOPA 300 MG CAPSULE, manufactured by Novadoz Pharmaceuticals LLC, is $1.8445 per EA (NDC 72205007490), effective Sep 30, 2026.
How has the price of DROXIDOPA 300 MG CAPSULE changed over time?
Over the history we have for it, the NADAC for DROXIDOPA 300 MG CAPSULE has declined 27.8%. It has been tracked across 172 weekly CMS publications since Jun 21, 2023.
What are the highest and lowest recorded NADAC prices for DROXIDOPA 300 MG CAPSULE?
Since Jun 21, 2023, the NADAC for DROXIDOPA 300 MG CAPSULE has ranged from a low of $1.8445 (Sep 23, 2026) to a high of $3.0478 (Nov 13, 2024), with a median of $2.5551 per EA.
Are there cheaper alternatives to DROXIDOPA 300 MG CAPSULE?
6 manufacturers publish a NADAC-priced product with the same active ingredient and strength as DROXIDOPA 300 MG CAPSULE in a comparable dosage form, but none are currently priced below it.
Who manufactures DROXIDOPA 300 MG CAPSULE?
DROXIDOPA 300 MG CAPSULE (NDC 72205007490) is labeled by Novadoz Pharmaceuticals LLC, and CMS classifies it as a generic product.